For the initial analyses based on IPF data, the number of patients experiencing an ALT and/or AST elevation ≥ 3 × ULN across the treatment groups was low (38 patients with events out of 895 nintedanib-treated patients and only 3 in the placebo group). This evidence concerns the gene GPT and idiopathic pulmonary fibrosis.